You are in: eMedicine Specialties > Emergency Medicine > PEDIATRIC Pediatrics, Scarlet FeverArticle Last Updated: Dec 19, 2007AUTHOR AND EDITOR INFORMATIONAuthor: Pamela L Dyne, MD, Associate Professor, Program Director, Department of Medicine, Division of Emergency Medicine, University of California at Los Angeles School of Medicine Pamela L Dyne is a member of the following medical societies: American College of Emergency Physicians and Society for Academic Emergency Medicine Coauthor(s): Peter Bloomfield, MD, MPH, Resident Physician, UCLA Medical Center/Olive View-UCLA Medical Center Emergency Medicine Residency Program Editors: Garry Wilkes, MBBS, FACEM, Director of Emergency Medicine, Bunbury Health Service, Western Australia Country Health Service; Adjunct Associate Professor, School of Exercise, Biomedical and Health Sciences, Faculty of Computing, Health and Science, Edith Cowan University; Medical Director, St John Ambulance Service; Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine.com, Inc; Grace M Young, MD, Associate Professor, Department of Pediatrics, University of Maryland Medical Center; John Halamka, MD, Chief Information Officer, CareGroup Healthcare System, Assistant Professor of Medicine, Department of Emergency Medicine, Beth Israel Deaconess Medical Center; Assistant Professor of Medicine, Harvard Medical School; Richard G Bachur, MD, Assistant Professor of Pediatrics, Harvard Medical School; Associate Chief and Fellowship Director, Attending Physician, Division of Emergency Medicine, Children's Hospital of Boston Author and Editor Disclosure Synonyms and related keywords: scarlatina, scarlatinella, scarlatiniform rash, group A streptococcal pharyngitis, strep throat, group A streptococci, group A beta-hemolytic streptococci, group A streptococcal toxin, strep throat, erythrogenic toxins, pharyngitis, petechiae on soft palate, flushed face with perioral pallor, anterior cervical lymphadenopathy, erythematous exanthem, Pastia sign, white strawberry tongue, red strawberry tongue INTRODUCTIONBackgroundScarlet fever is a syndrome characterized by exudative pharyngitis, fever, and scarlatiniform rash. It is caused by an infection with a pyogenic exotoxin-producing group A beta-hemolytic streptococci. PathophysiologyStreptococci are gram-positive cocci that grow in chains. They are classified by their ability to produce a zone of hemolysis on blood agar and by differences in carbohydrate cell wall components (A-H and K-T). Streptococci may be alpha-hemolytic (partial hemolysis), beta-hemolytic (complete hemolysis), or gamma-hemolytic (no hemolysis). Most streptococci excrete hemolyzing enzymes and toxins. Erythrogenic toxins cause the rash of scarlet fever. The erythema-producing toxin was discovered by Dick and Dick in 1924. Group A streptococci are normal inhabitants of the nasopharynx. Group A streptococci can cause pharyngitis, skin infections (including erysipelas pyoderma and cellulitis), pneumonia, bacteremia, and lymphadenitis. Scarlet fever is usually associated with pharyngitis; however, in rare cases, it follows streptococcal infections at other sites. Infections occur year-round, but the incidence of pharyngeal disease is highest in school-aged children (5-15 y) during winter and spring and in a setting of crowding and close contact. Person-to-person spread by means of respiratory droplets is the most common mode of transmission. It can rarely be spread through contaminated food, as seen in a recent outbreak in The incubation period for scarlet fever ranges from 12 hours to 7 days. Patients are contagious during the acute illness and during the subclinical phase. FrequencyUnited StatesUp to 10% of the population contracts group A streptococcal pharyngitis. Of this group, up to 10% then develop scarlet fever. Mortality/MorbidityIn the preantibiotic era, infections due to group A beta-hemolytic streptococci were major causes of mortality and morbidity. Now with antibiotics, enhanced immune status of the population and improved socioeconomic conditions, the incidence and rate of complications of these infections has decreased. SexNo predilection is observed. AgeScarlet fever predominantly occurs in children aged 5-15 years. CLINICALHistory
Physical
CausesScarlet fever results from an erythrogenic toxin produced by group A streptococci. DIFFERENTIALSDermatitis, Exfoliative Erythema Multiforme Mononucleosis Pediatrics, Fifth Disease or Erythema Infectiosum Pediatrics, Kawasaki Disease Pediatrics, Measles Pediatrics, Pharyngitis Pediatrics, Pneumonia Pediatrics, Rubella Pityriasis Rosea Scabies Staphylococcal Scalded Skin Syndrome Syphilis Toxic Epidermal Necrolysis Toxic Shock Syndrome
|
| Drug Name | Penicillin (Bicillin L-A, Beepen-VK, Pen-Vee K) |
|---|---|
| Description | Inhibits biosynthesis of cell-wall mucopeptide. Bactericidal against sensitive organisms when adequate concentrations reached and most effective during stage of active multiplication. Inadequate concentrations may produce only bacteriostatic effects. If patients have supportive complications, increased doses may be required. May be administered PO as penicillin VK (Beepen-VK, Pen-Vee K) or IM as penicillin G benzathine (Bicillin L-A). |
| Adult Dose | Penicillin VK: 250-500 mg PO qid for 10 d Penicillin G benzathine: 1.5 million U IM once |
| Pediatric Dose | Penicillin VK: <12 years: 25-50 mg/kg/d PO divided qid; not to exceed 3 g/d >12 years: Administer as in adults Penicillin G benzathine: <12 years: 25,000-50,000 U/kg IM once; not to exceed 1.2 million U/dose >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | Probenecid may increase effectiveness by decreasing clearance; tetracyclines are bacteriostatic, decreasing effectiveness of penicillins when administered concurrently |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Caution in renal impairment |
| Drug Name | Erythromycin (E.E.S.) |
|---|---|
| Description | Inhibits bacterial growth, possibly by blocking dissociation of peptidyl t-RNA from ribosomes, causing RNA-dependent protein synthesis to arrest. For treatment of staphylococcal and streptococcal infections. Appropriate therapy for patients allergic to penicillin. |
| Adult Dose | 250 mg PO qid for 10 d |
| Pediatric Dose | 30-50 mg/kg/d PO divided qid for 10 d |
| Contraindications | Documented hypersensitivity; hepatic impairment |
| Interactions | Coadministration may increase toxicity of theophylline, digoxin, carbamazepine, and cyclosporine; may potentiate anticoagulant effects of warfarin; coadministration with lovastatin and simvastatin, increases risk of rhabdomyolysis |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Caution in liver disease; estolate formulation may cause cholestatic jaundice; GI adverse effects are common (give doses pc); discontinue use if nausea, vomiting, malaise, abdominal colic, or fever occur |
The authors and editors of eMedicine gratefully acknowledge the contributions of previous author, Kelli N McCartan, MD, to the development and writing of this article.
Pediatrics, Scarlet Fever excerpt
Article Last Updated: Dec 19, 2007